Answers are grounded in this paper and cite their sources.
This review discusses antigen selection for Group A Streptococcus vaccines, highlighting challenges and opportunities.
Group A Streptococcus (GAS) remains a major global health challenge, causing over half a million deaths annually. Despite nearly a century of research, no licensed vaccine is currently available, due to antigenic diversity, complex host-pathogen interactions, risk of autoimmunity and lack of clear correlates of protection. This review discusses recent advances in GAS vaccine research, highlights key challenges and outlines criteria and emerging opportunities for antigen selection.
No takes yet. Share an insight, caveat, or question.
Belete et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: